نتایج جستجو برای: vaccine dna

تعداد نتایج: 607386  

2017
Pengxia Song Shenyi He Aihua Zhou Gang Lv Jingjing Guo Jian Zhou Yali Han Huaiyu Zhou Zhen Hao Hua Cong

BACKGROUND A widely prevalent disease, toxoplasmosis poses serious health threats to both humans and animals; therefore, development of an ideal DNA vaccine against Toxoplasma gondii is needed eagerly. The purpose of the present study is to assess the protective efficacy of a DNA vaccine encoding the T. gondii toxofilin gene (pEGFP-toxofilin). In addition, toxofilin DNA vaccine combined with th...

Journal: :Journal of virology 2015
Megan C Wise Natalie A Hutnick Justin Pollara Devin J F Myles Constance Williams Jian Yan Celia C LaBranche Amir S Khan Niranjan Y Sardesai David Montefiori Susan W Barnett Susan Zolla-Pazner Guido Ferrari David B Weiner

UNLABELLED The search for an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine remains a pressing need. The moderate success of the RV144 Thai clinical vaccine trial suggested that vaccine-induced HIV-1-specific antibodies can reduce the risk of HIV-1 infection. We have made several improvements to the DNA platform and have previously shown that improved DNA vaccines alone are cap...

Journal: :Vaccine 2009
Inga I Hitzeroth Jo-Ann S Passmore Enid Shephard Debbie Stewart Martin Müller Anna-Lise Williamson Edward P Rybicki W Martin Kast

The ability to elicit cross-neutralizing antibodies makes human papillomavirus (HPV) L2 capsid protein a possible HPV vaccine. We examined and compared the humoral response of mice immunized with a HPV-16 L2 DNA vaccine or with HPV-16 L2 protein. The L2 DNA vaccine elicited a non-neutralizing antibody response unlike the L2 protein. L2 DNA vaccination suppressed the growth of L2-expressing C3 t...

2015
Michelle C. Crank Ingelise J. Gordon Galina V. Yamshchikov Sandra Sitar Zonghui Hu Mary E. Enama LaSonji A. Holman Robert T. Bailer Melissa B. Pearce Richard A. Koup John R. Mascola Gary J. Nabel Terrence M. Tumpey Richard M. Schwartz Barney S. Graham Julie E. Ledgerwood

BACKGROUND A novel, swine-origin influenza A (H1N1) virus was detected worldwide in April 2009, and the World Health Organization (WHO) declared a global pandemic that June. DNA vaccine priming improves responses to inactivated influenza vaccines. We describe the rapid production and clinical evaluation of a DNA vaccine encoding the hemagglutinin protein of the 2009 pandemic A/California/04/200...

2014
Yuxin Chen Shixia Wang Shan Lu

DNA vaccination has been studied in the last 20 years for HIV vaccine research. Significant experience has been accumulated in vector design, antigen optimization, delivery approaches and the use of DNA immunization as part of a prime-boost HIV vaccination strategy. Key historical data and future outlook are presented. With better understanding on the potential of DNA immunization and recent pr...

Journal: :Molecular therapy : the journal of the American Society of Gene Therapy 2007
Chang-Yao Hsieh Chi-An Chen Chia-Yen Huang Ming-Cheng Chang Chien-Nan Lee Yi-Ning Su Wen-Fang Cheng

A naked DNA vaccine delivered by gene gun into antigen-presenting cells (APCs) has emerged as an attractive strategy for antigen-specific cancer immunotherapy. However, APCs have a limited lifespan, hindering their long-term ability to prime antigen-specific T cells. Furthermore, the potency of DNA vaccines is limited by their inability to process and present antigens. Interleukin-6 (IL-6) coul...

Journal: :Journal of immunology 2002
Petra Riedl Shereen El-Kholy Jörg Reimann Reinhold Schirmbeck

The immunodominant, conformational "a" determinant of hepatitis B surface Ag (HBsAg) elicits Ab responses. We selectively expressed the Ab-binding, glycosylated, native a determinant (residue 120-147) of HBsAg in a fusion protein containing C-terminally the HBsAg fragment SII (residue 80-180) fused to a SV40 T-Ag-derived hsp73-binding 77 aa (T(77)) or non-hsp-binding 60 aa (T(60)) N terminus. A...

Motalleb Gholamreza, Ahmad Yegane Moghadam, Binabaj Maryam Moradi , Malihe Naderi, Mohammad Reza Zolfaghari, Naghmeh Gholipour,

The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...

Journal: :The New England journal of medicine 2013
Scott M Hammer Magdalena E Sobieszczyk Holly Janes Shelly T Karuna Mark J Mulligan Doug Grove Beryl A Koblin Susan P Buchbinder Michael C Keefer Georgia D Tomaras Nicole Frahm John Hural Chuka Anude Barney S Graham Mary E Enama Elizabeth Adams Edwin DeJesus Richard M Novak Ian Frank Carter Bentley Shelly Ramirez Rong Fu Richard A Koup John R Mascola Gary J Nabel David C Montefiori James Kublin M Juliana McElrath Lawrence Corey Peter B Gilbert

BACKGROUND A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increased risk for HIV-1 infection in the United States. METHODS At 21 sites, we randomly assigned 2504 men or transgender women who have sex ...

Journal: :Vaccine 2008
Alain Luxembourg Drew Hannaman Ken Wills Robert Bernard Bud C Tennant Stephan Menne Paul J Cote

The licensed vaccine against hepatitis B virus (HBV) is an effective means to prevent infection, but is not an effective therapeutic strategy to treat established chronic infections when used alone. In an animal model of chronic HBV infection (the woodchuck experimentally infected with woodchuck hepatitis virus (WHV)), the combination of conventional vaccine and potent antiviral drugs has shown...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید